Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Cytomegalovirus (CMV) test1 is now commercially available in Europe. CMV viral load testing helps physicians manage immunocompromised patients at risk of CMV disease, including those who have undergone solid organ and stem cell transplantation. This standardized and fully automated test monitors CMV infections using an easy-to-operate system capable of delivering accurate and reliable results to clinicians so that they can make critical treatment decisions.
